Fermented Dairy Ingredients Market Research Report, Share, Size and Forecast for 2032

The market for fermented dairy ingredients is anticipated to expand between 2022 and 2032 at a CAGR of 8%. The market for fermented dairy ingredients is anticipated to grow from US$7.3 billion in 2022 to US$16.1 billion by 2032.

In recent years, the demand for nutritious supplements has skyrocketed, particularly in underdeveloped nations where malnourishment is still a serious problem. Dairy products that have undergone fermentation are becoming more popular in both developed and developing nations as a major source of nutrients.

Check the sample report available in PDF format@
https://www.futuremarketinsights.com/reports/sample/rep-gb-4372

Food and Agriculture Organization (FAO), revealed that approximately 150 million households are currently engaged in milk production across the globe. Over the last three decades, the global milk production has increased by over 50%, from 500 million tonnes in 1983 to 769 million tonnes in 2013.

As per the report, the global fermented dairy market is slated to reach a valuation of US$ 4,856.5 Mn by the end of 2022. Increasing per capita expenditure on dairy products is expected to favour the future prospects of the global fermented dairy ingredients market. The report also assesses that fermented dairy ingredients are likely to face stern competition from cheaper alternatives available in the market.

In addition, growing consumer preference for alternative products such as probiotics and other supplements is expected to dampen the surging spirit of the global fermented dairy ingredients market to a certain extent. Fluctuating prices of fermented dairy products and unsafe handling process that compromises product safety and quality is also subduing the growth of the market in regions such Europe and Asia Pacific.

Ask to Analyst@
https://www.futuremarketinsights.com/ask-question/rep-gb-4372 

By product type, cheese currently accounts for the largest value share of the market followed by flavoured milk. This is primarily owing to the growing interest of dairy ingredient manufacturers to bring new innovative cheese products with unique flavours and improved textures in order to increase the product value. Meanwhile, the yoghurt segment is projected to witness the fastest CAGR, as the global consumption of yoghurt is on the rise.

Among regions, the market in Western Europe accounted for the largest revenue share in 2016, reaching a valuation of US$ 1,366 Mn. Towards the end of forecast period, the region’s market is expected to stand at US$ 3,575.7 Mn, expanding at a CAGR of 9.2%. The abolition of milk quota system and increasing demand for frozen and freeze-dried starter dairy cultures is driving the market for fermented dairy ingredients in Western Europe.

Asia Pacific (APEC) and North America are the two other lucrative markets for fermented dairy ingredients. Between 2017 and 2027, the market in APEJ is set to witness a robust CAGR of 10.5%, which is credited to the rising popularity of flavoured milk among consumers across China and Australia.

Some of the leading companies profiled in the report include Koninklijke DSM N.V., E. I. du Pont de Nemours and Company, Chr. Hansen Holding A/S, Cargill Incorporated, Bioprox (A subsidiary of Proxis Développement), Novozymes, Kerry Inc, Archer Daniels Midland Company, Ingredion Incorporated, Arla Foods Ingredients Group P/S, Lake International Technologies, DairyChem Inc., CSK Food Enrichment, CP Ingredients Limited, Epi Ingredeints, Dairy Connection Inc., Socius Ingredients LLC, The Tatua Cooperative Dairy Company Ltd, Koninklijke DSM NV, Corbion.

Manufacturers are providing ingredients according to specific requirements of the client. Also, many of the players are actively focusing on launching variety of ingredients in the market to increase their consumer base.

Buy Report Now@
https://www.futuremarketinsights.com/checkout/4372 

Fermented Dairy Ingredients Market by Category

By Product Type:

  • Cheese
    • Natural Cheese
      • Cultures
      • Enzymes
      • Starch
        • Modified Starch
        • Native Starch
      • Sweetener
    • Processed Cheese
      • Cultures
      • Enzymes
      • Starch
        • Starch Modified
        • Starch Native
    • Sweetener
  • Flavoured Milk:
    • Cultures
    • Enzymes
    • Starch
    • Starch Modified
    • Starch Native
    • Sweetener
  • Yogurt:
  • Spoonable Yogurt
    • Cultures
    • Enzymes
    • Starch
      • Starch Modified
      • Starch Native
  • Sweetener
  • Drinkable Yogurt
    • Cultures
    • Enzymes
    • Starch
      • Starch Modified
      • Starch Native
    • Sweetener

By Application:

  • Bakery
  • Dairy
  • Snacks
  • Others

About FMI

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization, and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel, and End Use over the next 10 years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse Other Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Surgical Tourniquets Market is projected to reach US$ 812.2 by 2029 | FMI Study

FMI’ analysis expects the surgical tourniquets market to grow at ~8% CAGR through to 2029, driven a surge in the number of trauma cases over the years lined with rising demand for effective device to stop arterial bleeding during surgical procedures. Analysts also expect that automatic machines and robotic technologies are likely to bring a paradigm shift in operative procedures, which should push the manufacturers to innovate their products and develop strategies to attract and retain a new segment of customers.

Worldwide sales of surgical tourniquets will increase by 7.5% year-over-year to reach ~US$ 381 million in 2019, up from ~US$ 355 million in 2018, according to the latest research from Future Market Insights (FMI).

Surgical tourniquets have long been reliable to establish a bloodless field of operation for surgeons while maintaining a high level of safety for patients. However, the risk of surgical-site infections as well as tourniquet-related injuries, particularly due to the application of high pressures and high pressure gradients to the patient, remains a potential threat to the market growth.

In an attempt to reduce the risks associated with higher tourniquet pressures, manufacturers are placing their bets on products innovations and introduction of novel features such as automatic pressure control, audiovisual alarms, digital displays, and easy-to-use user interface.

Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2254

Sales of Tourniquet Cuffs to Ramp up in 2019

According to the FMI analysts, tourniquet cuffs have been a vital part of the modern computer-assisted tourniquet system, which accounted for ~77% of total market revenue in 2018. While the inflatable disposable cuffs represented more than half of the total tourniquet cuff sales in 2018, the consumption of inflatable reusable cuffs is likely to increase 7.6% y-o-y in 2019.

“In terms of tourniquet systems, dual channel systems will continue to represent a relatively high share as compared to single channel systems, in the view of enabling bi-lateral procedures or simultaneous surgeries of both upper and lower extremity,” the FMI analyst said.

The consumption of surgical tourniquets for knee arthroplasty accounted for ~31% sales in 2018, while increasing application in amputation of limbs and trauma cases is likely to result in increased market share in the future.

“Recent advancements in reverse shoulder arthroplasty along with the introduction of ‘personalized’ tourniquet systems that allow the use of variable contour design and cuffs for specific patients will open new avenues of growth for the market players,” said the FMI analyst.

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-2254

Hospitals Capture Significant Share, North America in the Vanguard

In 2018, surgical tourniquets worth ~US$ 176 million were sold in hospitals; according to the FMI analysts, growing number of hospitals, especially in developing countries, and greater awareness of advanced medical devices will continue to drive the consumption of surgical tourniquets in hospitals.

Rapid adoption of ‘value-based’ model in health care settings have led to a surge in the number of ambulatory surgical centers and specialized clinics, thereby paving a new way of growth for the surgical tourniquets market.

The FMI analyst forecasts that North America will continue to remain at the forefront of surgical tourniquets market, representing 30% share in 2018. While North America is likely to be neck-and-neck with Europe to lead the market in future, manufacturers are tapping into new opportunities in developing countries in Asia Pacific.

The surgical tourniquets market shows a fair level of fragmentation, with two prominent players including Zimmer Biomet and Stryker Corporation accounting for more than one-third of the total revenue share. Exploring unmet needs in developing regions and expanding their distribution through collaboration and acquisitions of local and regional manufacturers remain key focal points of the market players.

Key Segment

By Product Type

  • Tourniquet Systems
    • Single Channel Systems
    • Dual Channel Systems
  • Tourniquet Cuffs
  • Inflatable Cuffs
    • Disposable Cuffs
    • Reusable Cuffs
  • Non-Inflatable Cuffs
    • Disposable Cuffs
    • Reusable Cuffs

By Application

  • Knee Arthroplasty
  • Amputation of Limbs
  • Plastic Surgeries
  • Trauma Cases

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Clinics

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-2254

By Region

  • North America
  • Europe
  • Latin America
  • South Asia
  • East Asia
  • Oceania
  • Middle East And Africa
  • Emerging Countries

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

MRI Pulse Oximeters Market to reach a valuation of US$ 36.5 Million by 2028 | FMI

Global sales of MRI pulse oximeters were valued at ~US$ 31.6 million in 2022, is predicted to increase at a CAGR of 2.5% to reach a valuation of US$ 36.5 Mn by 2028. As per the research findings of a new study by Future Market Insights (FMI), constant technological advancements in medical devices that target improved efficiency and convenience, have been sustaining the use of MRI pulse oximeters.

A notable increase in the prevalence of chronic diseases has led to surge in the sales of high-end diagnostic machines, including those for MRI, and CT scanners, which in turn foster the demand for MRI pulse oximeters. Developed with non-magnetic components, MRI-compatible pulse oximeters have been gaining ground in early detection of critical congenital heart defects (CCHD) by accurately measuring the blood oxygen value of a newborn.

Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-10020

FMI study estimates that the MRI pulse oximeters market will register a CAGR of 2.5% during the given timeframe. High costs associated with MRI procedures have been creating a wave of reluctance among healthcare professionals and patients to adopt MRI pulse oximetry testing.

Wireless MRI Pulse Oximeters Capture Significant Shares

Aligning with the rapid development of state-of-the-art medical devices and technologies, market players continue to increase the production of wireless MRI pulse oximeters that need not be connected to MRI machines. Operated through infrared (IR) or Bluetooth technology, wireless MRI pulse oximeters have also witnessed higher innovations and investments as compared to wired variants. As 6 in 10 units of MRI pulse oximeters sold in 2021 are wireless, manufacturers are specifically focused in this category. Additionally, MRI pulse oximeters without monitor continue to account for greater revenue share over their counterparts, as they can be coupled with a wide range of monitors.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-10020

According to the study, while business growth strategies remained influenced by the increasing adoption of MRI pulse oximeters in hospitals, manufacturers are working towards capitalizing on diagnostic laboratories and ambulatory surgical centers for expanded customer base. Increasing patient visits in well-equipped laboratories for complete diagnosis of diseases has also led to realignment of these strategies.

Growth prospects of the MRI pulse oximeters market, as identified by the FMI study, are high in North America. Heavy investments in R&D activities on medical devices and technologies along with favorable reimbursement scenario in the region are likely to offer lucrative opportunities for the market players. In addition, manufacturers are viewing Asia Pacific from target market perspective, considering increasing healthcare expenditure and growing awareness of new medical devices in the region.

Key Key Segments of MRI Pulse Oximeters Industry Research

MRI Pulse Oximeters Market by Product Type:

  • Wired MRI Pulse Oximeters
  • Wireless MRI Pulse Oximeters

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/10020

MRI Pulse Oximeters Market by Modality:

  • Sensors with Monitors
  • Sensors without Monitors

MRI Pulse Oximeters Market by End User:

  • Hospitals
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers

MRI Pulse Oximeters Market by Region:

  • North America MRI Pulse Oximeters Market
  • Latin America MRI Pulse Oximeters Market
  • Europe MRI Pulse Oximeters Market
  • East Asia MRI Pulse Oximeters Market
  • South Asia & Pacific MRI Pulse Oximeters Market
  • Middle East & Africa (MEA) MRI Pulse Oximeters Market

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Glucose Monitoring Devices Market in USA is expected to register a growth of 16.1% by 2033 | Says FMI Analyst

According to Future Market Insights’ most recent industry report, the global Glucose Monitoring Devices Market was valued at roughly US$ 21.3 Billion in 2022 and is expected to rise at a CAGR close to 16.9% over the forecast period, reaching an estimated worth of US$ 118.1 Billion in 2033.

Over the past 20 years, diabetes has escalated to a severe health concern with an unparalleled rate of global growth. It is a significant contributor to death in those aged 20 to 79. The World Health Organization has classified diabetes as a global pandemic due to its rapidly increasing prevalence.

Patients with diabetes require regular monitoring. Costs associated with patient monitoring can be decreased by utilizing technologies for information and communication, artificial intelligence, and smart devices together. Diabetes is mostly brought on by changes in blood glucose levels, and it is important to keep them steady for a set period.

Get a PDF Sample with the Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16747

The adoption of continuous glucose monitoring devices, which are emerging as a novel technique for monitoring glucose levels, is growing along with the number of diabetic patients. Every ten minutes, these devices update the real-time glucose level data they provide. The preservation of healthy blood glucose level is the only method for a diabetic to prevent potentially fatal diabetic complications, and glucose monitoring is an essential component of diabetes management.

Non-invasive glucose monitoring has recently become more popular as it lessens the discomfort and suffering experienced by diabetics who must prick their skin more than four times per day to measure their blood glucose levels.

With increasing prevalence of diabetes, as well as advancements in sensor-based technologies for patient monitoring, the market is set to expand at a lucrative pace, over the forecast period.

Key Takeaways from Market Study

  • Self-monitoring devices are the leading segment as product, and hold approximately 3% market value share in 2022, owing to their automated and reliable monitoring process.
  • Diabetes type II segment is set to lead in terms of indication of glucose monitoring devices with an estimated market value share of around 1% by 2023, owing to the high prevalence of type II diabetes globally.
  • By end user, hospitals held a market share of around 7% in 2022, owed to the adoption of continuous monitoring devices in hospitals to reduce the number of fingerstick point of care capillary blood glucose tests, hyperglycemic episodes, and hypoglycemic episodes.
  • North America holds a value share of 0% in 2022, owing to the high prevalence of chronic diseases in the region.

Last few days to get reports at discounted prices, the offer expires soon!
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-16747

“Rising initiatives to integrate artificial intelligence, as well as digital technologies to blood glucose monitoring devices, as well as growing new product launch activities, are factors propelling the growth of the global glucose monitoring market,” says an analyst of Future Market Insights.

Market Competition

Key players’ rigorous research led to the development of improved technologies such as flash glucose monitoring and continuous glucose monitoring. Companies also engage in strategic initiatives such as new product launches and mergers and acquisitions.

  • All consumers with diabetes type 1 are now covered for the Dexcom G6 rtCGM System under the Non-Insured Health Benefits Program, according to an announcement made by Dexcom, Inc. in January 2023.
  • Abbott disclosed in June 2022 that it is creating a new biowearable that combines a sensor to continually monitor both glucose and ketone levels. The U.S. FDA has granted the system breakthrough device classification.

Key Market Players:

  • Dexcom, Inc.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Medtronic
  • Ascensia Diabetes Care
  • Arkray
  • Ypsomed AG
  • Acon Laboratories
  • Nipro
  • Nova Biomedical
  • Goldsite Diagnostics Inc. (China)
  • Lifescan Ip Holdings, LLC
  • Prodigy Diabetes Care
  • Others

Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16747

Key Market Segments Covered in Glucose Monitoring Devices Industry Research

Product:

  • Self-Monitoring Devices
  • Continuous Monitoring Devices

Indication:

  • Diabetes Type I
  • Diabetes Type II

End User:

  • Hospitals
  • Clinics
  • Diagnostics Centres
  • Home Care Settings

About Future Market Insights (FMI) 

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs

Castration-Resistant Prostate Cancer (CRPC) Treatment Market is expected to reach US$ 28 Billion by 2033, at a CAGR of 9.5%

According to Future Market Insights, the Castration-Resistant Prostate Cancer (CRPC) Treatment Market is predicted to develop at a 9.5% CAGR from 2023 to 2033. The global market for Castration-Resistant Prostate Cancer (CRPC) Treatment is estimated to reach a value of US$ 28 billion by 2033.

Growth of the market can be attributed to increasing prevalence of CRPC, coupled with the growing awareness and diagnosis of the disease, is one of the key drivers of this growth. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.

Another important factor driving the growth of the CRPC treatment market is the increasing use of combination therapies. By using a combination of different drugs and treatments, physicians can better target the cancer and improve treatment outcomes. For example, combining targeted therapies with immunotherapies has shown promise in early studies.

Get a PDF Sample with the Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16739

One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies around the world.

Key Takeaways from the Market Study

  • Castration-Resistant Prostate Cancer (CRPC) Treatment market expected to grow at a value of 9.5% CAGR during the forecast period 2023-2033.
  • By drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
  • North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
  • Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

“The development of new targeted therapies, immunotherapies, and combination therapies is driving this growth, and there is significant potential for continued innovation in the years to come.” states an FMI analyst

Ask Us Your Questions About This Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-16739

Competitive Landscape

Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation

  • Sanofi, a key player in CRPC treatment market is involved in the development of other drugs for the treatment of cancer more broadly, including immunotherapies and targeted therapies.
  • in 2019, Abbott announced the launch of a new clinical trial to investigate the use of their drug, ABT-199, in combination with enzalutamide (Xtandi) for the treatment of metastatic CRPC. ABT-199 is a targeted therapy that works by inhibiting a protein called BCL-2, which is overexpressed in many cancer cells.

Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey

Therapy Type:

  • Hormonal therapy
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy

For more Report Customization, connect with us @ https://www.futuremarketinsights.com/customization-available/rep-gb-16739

Drug Class:

  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor

Drug Delivery Method:

  • Oral Route
  • Injectable Route

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

About Future Market Insights (FMI) 

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs

Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Register 4.9% CAGR from 2023 to 2033 | FMI Study

During the forecast period 2023 to 2033, the Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market is expected to grow at a value of 4.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Atypical hemolytic uremic syndrome (ahus) treatment is expected to rise up to a market valuation of US$ 2308.84 Million. Growth of the market can be attributed to increasing prevalence of the disease, rising awareness among healthcare professionals, and the introduction of innovative therapies that offer improved efficacy and safety profiles.

The market for aHUS treatment is also benefiting from increasing awareness of the disease among healthcare professionals and patients. As more physicians become familiar with the symptoms and diagnosis of aHUS, patients are more likely to receive a timely and accurate diagnosis, which can improve their chances of a favorable outcome.

Learn about the contribution of each segment of the market. Read a Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16735

In addition, pharmaceutical companies are investing in research and development of new therapies for aHUS, which is leading to the introduction of new treatments with improved efficacy and safety profiles. This is creating a competitive landscape for aHUS treatment, with companies vying for market share through the development of innovative therapies and effective marketing strategies.

Key Takeaways from the Market Study

  • The Atypical hemolytic uremic syndrome (ahus) treatment market is expected to grow at a value of 4.9% CAGR in the forecast period 2023-3033.
  • By distribution channel, hospitals are expected to hold 45% of the market share in 2023 for Atypical hemolytic uremic syndrome (ahus) treatment market.
  • North America is expected to possess 44% market share for Atypical hemolytic uremic syndrome (ahus) treatment market in 2023.
  • Europe Atypical hemolytic uremic syndrome (ahus) treatment market size is expected to possess 38% market share in 2023.

“The market is also likely to benefit from the growing demand for personalized medicine, as patients with aHUS may require different treatment approaches based on their individual genetic and medical profiles.” states an FMI analyst

Interested in Procure The Data? Inquire here: https://www.futuremarketinsights.com/ask-question/rep-gb-16735

Competitive Landscape

Key players in the atypical hemolytic uremic syndrome (ahus) treatment market are Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Tasly Biopharmaceuticals, Prestige BioPharma, Abbott Medtronic, Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc.

  • Omeros Corporation, a key player in the atypical hemolytic uremic syndrome (ahus) treatment market is offering narsoplimab (also known as OMS721), which is a first-in-class monoclonal antibody that targets the lectin pathway of the complement system. The lectin pathway is one of the three pathways in the complement system that can become overactivated in patients with aHUS.
  • Novartis has been involved in research into other potential treatments for aHUS. One of the most promising of these is iptacopan (LNP023), a first-in-class oral inhibitor of the complement system.

Buy This Report: https://www.futuremarketinsights.com/checkout/16735

Key Segments Profiled in the Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Industry Survey

Product Type:

  • Mono
  • Combination
  • Mono/Combination

Molecule Type:

  • Monoclonal Antibody
  • Peptides

Polymer:

  • Small molecule
  • Gene therapy

Route of Administration:

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

About Future Market Insights (FMI) 

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs

Rosai-Dorfman Disease (RDD) Therapeutics Market is expected to grow with a 6.9% CAGR during 2023 to 2033

According to Future Market Insights, the Rosai-Dorfman Disease (RDD) Therapeutics market is predicted to increase at a 6.9% CAGR from 2023 to 2033. The global market for Rosai-Dorfman Disease (RDD) Therapeutics is estimated to reach US$ 839.95 Million by the year 2033.

Advances in diagnostic technologies and the development of novel medicines are projected to fuel significant growth in the global RDD therapeutics market in the coming years.

RDD is typically diagnosed through a combination of clinical examination, imaging studies, and tissue biopsy. Once a diagnosis is confirmed, treatment options include watchful waiting, corticosteroid therapy, radiation therapy, and surgery. However, current treatments are often ineffective and can cause significant side effects, highlighting the need for more effective and targeted therapeutics.

Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16716

Key companies are exploring the use of immune checkpoint inhibitors, such as PD-1 inhibitors, to treat RDD. These therapies work by blocking the immune checkpoints that cancer cells use to evade detection and destruction by the immune system. While still in early stages of development, these therapies hold great promise for the treatment of RDD.

Key Takeaways from the Market Study

  • The Rosai-Dorfman Disease (RDD) Therapeutics market is expected to grow at a value of 6.9% CAGR in the forecast period 2023-2033
  • By distribution channel, hospital pharmacies are expected to possess 46% market share for Rosai-Dorfman Disease (RDD) Therapeutics market in 2023.
  • North America is expected to possess 40% market share for Rosai-Dorfman Disease (RDD) Therapeutics market in 2023.
  • Asia Pacific is expected to possess 35% market share for Rosai-Dorfman Disease (RDD) Therapeutics market in 2023.

“Development of targeted therapeutics and personalized medicine is expected to provide significant growth opportunities in the coming years.” states an FMI analyst

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-16716

Competitive Landscape

  • Teva Pharmaceuticals Ltd, a key player in the Rosai-Dorfman Disease (RDD) Therapeutics market is focusing on investing in research and development to innovate medication for treating the ailment.
  • Zydus Pharmaceuticals, Inc, another key player in the Rosai-Dorfman Disease (RDD) Therapeutics market is focusing on integrating technology to understand the nature of the ailment and innovate medication for early-stage treatment.

Key players:

  • Teva Pharmaceuticals Ltd.
  • Zydus Pharmaceuticals, Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Advanz Pharmaceticals
  • Novartis AG
  • Mylan N.V.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd
  • Viatris Inc.
  • Pfizer Inc.

Order a Complete Research Report @ https://www.futuremarketinsights.com/checkout/16716

Key Segments Profiled in the Rosai-Dorfman Disease (RDD) Therapeutics Industry Survey

Drug Class:

  • MEK-inhibitors
    • Cobimetinib
    • Trametinib
    • Binimetinib
  • Immunosuppressants and modulators
    • Mercaptopurine
    • Azathioprine
    • Lenalidomide
    • Thalidomide
  • Chemotherapy
    • Cladribine
    • Cytarabine
    • Vinblastine
    • Hydroxyurea
    • Methotrexate

Treatment:

  • PET Scan
  • CT scan
  • MRI
  • Ultrasounds
  • Blood Tests

End User:

  • Hospitals
  • Clinical Laboratories

Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

About Future Market Insights (FMI) 

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs

Ferric Sulfate Market Size is Anticipated to Grow at a CAGR of 3.9% from 2022 to 2032

As per the recent research conducted by a leading market insights provider FMI, the global Ferric Sulfate market will expand at a healthy CAGR over the forecast period between 2022 and 2032. The aim of this study is to analyze key market dynamics affecting the sales of Ferric Sulfate and provide vital insights to business owners to get benefited from forthcoming opportunities.

The report conducts an in-depth analysis into factors affecting the change in consumer behavior and purchasing patterns. It highlights the key growth prospects for the demand and sales across seven major regions. It also provides refines sales projections and assist market players in identifying the remunerative segments among the verticals.

Upsurge in the Trend of Green Chemistry to Facilitate the Growth in the Ferric Sulfate Market

Governments of several countries are emphasizing on implementing regulations on chemicals that are hazardous for environment, owing to the rising concerns regarding environment sustainability. Hence, growing trend of green chemistry or sustainable chemistry is being witnessed across the chemical industry.

Citing this trend, chemical manufacturers are reviewing their business strategies and shifting their focus towards adopting eco-friendly practices for the production of sustainable alternatives or less toxic chemicals. This is expected to favor the growth in the Ferric Sulfate market.

For details on vendors and their offerings – Request a sample report: https://www.futuremarketinsights.com/reports/sample/rep-gb-375

Key Ferric Sulfate Market Takeaways and Projections

  • The U.S. will lead the North America Ferric Sulfate market, projecting the fastest growth in the region between forecast period
  • Germany will collectively hold the largest share in the Europe market over the assessment period.
  • India will emerge as a highly remunerative market in South Asia, contributing significant revenue share in the region through forecast period.
  • China will dominate the East Asia market, accounting for the largest demand share during the forecast period.
  • In terms of segments, will hold the lion’s share in the market, expanding at a robust CAGR during the next ten years.

Competitive Landscape Analysis

The survey offers insights into critical trends and opportunities across technology industry and studies their impact on demand-supply forces in the Ferric Sulfate market. It also profiles a list of prominent companies including Alfa Aesar, Beijin Ouhe Technology Co Ltd, Chengdu XiYa Chemical Technology Co Ltd and Nanjing Vital Chemical Co Ltd

Request for TOC @ https://www.futuremarketinsights.com/toc/rep-gb-375

Regional analysis includes

  • North America
  • US & Canada
  • Latin America
  • Brazil, Mexico, Others
  • Western Europe
  • EU5
  • Nordics
  • Benelux
  • Eastern Europe
  • Asia Pacific
  • Australia and New Zealand (ANZ)
  • Greater China
  • India
  • ASEAN
  • Rest of Asia Pacific
  • Japan
  • Middle East and Africa
  • GCC Countries
  • Other Middle East
  • North Africa
  • South Africa
  • Other Africa

Why Buy FMI’s Report?

  • Extensive analysis on high growth niche markets across major regions
  • Detailed assessment on key segments and sub-segments
  • Recent and upcoming strategies tracked of manufacturers for the Ferric Sulfate market
  • Reliable information on new product launches, technological advancements, and more
  • Valuable insights on the impact of regulatory framework on the global Ferric Sulfate market

About FMI

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
LinkedIn| Twitter| Blogs

Sales of Asia Pacific Industrial Solvents Market to Reach of US$ 25,409.8 million by 2033

As per the recent research conducted by a leading market insights provider FMI, the global Asia Pacific Industrial Solvents market will expand at a healthy CAGR over the forecast period between 2023 and 2033. The aim of this study is to analyze key market dynamics affecting the sales of Asia Pacific Industrial Solvents and provide vital insights to business owners to get benefited from forthcoming opportunities.

The report conducts an in-depth analysis into factors affecting the change in consumer behavior and purchasing patterns. It highlights the key growth prospects for the demand and sales across seven major regions. It also provides refines sales projections and assist market players in identifying the remunerative segments among the verticals.

Upsurge in the Trend of Green Chemistry to Facilitate the Growth in the Asia Pacific Industrial Solvents Market

Governments of several countries are emphasizing on implementing regulations on chemicals that are hazardous for environment, owing to the rising concerns regarding environment sustainability. Hence, growing trend of green chemistry or sustainable chemistry is being witnessed across the chemical industry.

Citing this trend, chemical manufacturers are reviewing their business strategies and shifting their focus towards adopting eco-friendly practices for the production of sustainable alternatives or less toxic chemicals. This is expected to favor the growth in the Asia Pacific Industrial Solvents market.

For details on vendors and their offerings – Request a sample report: https://www.futuremarketinsights.com/reports/sample/rep-ap-280

Key Asia Pacific Industrial Solvents Market Takeaways and Projections

  • The U.S. will lead the North America Asia Pacific Industrial Solvents market, projecting the fastest growth in the region between forecast period
  • Germany will collectively hold the largest share in the Europe market over the assessment period.
  • India will emerge as a highly remunerative market in South Asia, contributing significant revenue share in the region through forecast period.
  • China will dominate the East Asia market, accounting for the largest demand share during the forecast period.
  • In terms of segments, will hold the lion’s share in the market, expanding at a robust CAGR during the next ten years.

Competitive Landscape Analysis

The survey offers insights into critical trends and opportunities across technology industry and studies their impact on demand-supply forces in the Asia Pacific Industrial Solvents market. It also profiles a list of prominent companies including

  • BASF SE
  • BP plc
  • ExxonMobil
  • LyondellBasell
  • Royal Dutch Shell
  • Petroleo Brasileiro S.A
  • DuPont
  • Total S.A.
  • SABIC
  • Diacel Chemical Industries Ltd
  • Harmony Organics Pvt Ltd
  • Eternis Fine Chemicals
  • IGPL
  • Eastman Chemical Company
  • Ashland Global Holdings Inc.
  • Celanese Corporation
  • Honeywell International
  • Gandhar Oil
  • INEOS

Request for TOC @ https://www.futuremarketinsights.com/toc/rep-ap-280

Key Segments Profiled in the Market

By Product Type, the market of industrial solvents has been segregated as:

  • Alcohols
    • Methanol
    • Ethanol
    • Butanol
    • Propanol
    • Others
  • Ketones
    • Acetone
    • Methyl Ethyl Ketone
    • Methyl Isobutyl Ketone
    • Others
  • Glycols
    • Ethylene Glycol
    • Propylene Glycol
    • Others
  • Esters
    • Ethyl Acetate
    • Butyl Acetate
    • Others
  • Glycol Esters
    • E-Series
    • P-Series
    • Butyl Glycol Ethers
    • Others
  • Aliphatic Solvents
  • Aromatic Solvents
    • Toluene
    • Benzene
    • Xylene
    • Ethyl Benzene
    • Others
  • Halogenated Solvents
    • Methylene Chloride
    • Trichloroethylene
    • Perchloroethylene
    • Others
  • Acetic Acid

By End-use Industry:

  • Chemical
  • Paints and Coatings
  • Textile
  • Pulp and Paper
  • Pharmaceuticals
  • Oil and Gas
  • Adhesives and Sealants
  • Personal Care and Cosmetics
  • Agriculture
  • Others

By Country:

  • China
  • Japan
  • South Korea
  • India
  • Vietnam
  • Indonesia
  • Philippines
  • Malaysia
  • Australia and New Zealand
  • Rest of Asia Pacific

Why Buy FMI’s Report?

  • Extensive analysis on high growth niche markets across major regions
  • Detailed assessment on key segments and sub-segments
  • Recent and upcoming strategies tracked of manufacturers for the Asia Pacific Industrial Solvents market
  • Reliable information on new product launches, technological advancements, and more
  • Valuable insights on the impact of regulatory framework on the global Asia Pacific Industrial Solvents market

About FMI

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
LinkedIn| Twitter| Blogs

Bio Polyol and Green Polyol Market Anticipated to be Appraised at US$ 10.61 Billion by 2032

As per the recent research conducted by a leading market insights provider FMI, the global Bio Polyol and Green Polyol market will expand at a healthy CAGR over the forecast period between 2022 and 2032. The aim of this study is to analyze key market dynamics affecting the sales of Bio Polyol and Green Polyol and provide vital insights to business owners to get benefited from forthcoming opportunities.

The report conducts an in-depth analysis into factors affecting the change in consumer behavior and purchasing patterns. It highlights the key growth prospects for the demand and sales across seven major regions. It also provides refines sales projections and assist market players in identifying the remunerative segments among the verticals.

Upsurge in the Trend of Green Chemistry to Facilitate the Growth in the Bio Polyol and Green Polyol Market

Governments of several countries are emphasizing on implementing regulations on chemicals that are hazardous for environment, owing to the rising concerns regarding environment sustainability. Hence, growing trend of green chemistry or sustainable chemistry is being witnessed across the chemical industry.

Citing this trend, chemical manufacturers are reviewing their business strategies and shifting their focus towards adopting eco-friendly practices for the production of sustainable alternatives or less toxic chemicals. This is expected to favor the growth in the Bio Polyol and Green Polyol market.

For details on vendors and their offerings – Request a sample report: https://www.futuremarketinsights.com/reports/sample/rep-gb-273

Key Bio Polyol and Green Polyol Market Takeaways and Projections

  • The U.S. will lead the North America Bio Polyol and Green Polyol market, projecting the fastest growth in the region between forecast period
  • Germany will collectively hold the largest share in the Europe market over the assessment period.
  • India will emerge as a highly remunerative market in South Asia, contributing significant revenue share in the region through forecast period.
  • China will dominate the East Asia market, accounting for the largest demand share during the forecast period.
  • In terms of segments, will hold the lion’s share in the market, expanding at a robust CAGR during the next ten years.

Competitive Landscape Analysis

The survey offers insights into critical trends and opportunities across technology industry and studies their impact on demand-supply forces in the Bio Polyol and Green Polyol market. It also profiles a list of prominent companies including Arkema S.A., BASF SE, Biobased Technologies LLC, Bayer MaterialScience, Cargill Inc., Global Bio-Chem Technology Group Co. Ltd., Emery Oleochemicals (M) Sdn Bhd, Johnson Controls Inc, and Jayant Agro Organics Ltd.

Request for TOC @ https://www.futuremarketinsights.com/toc/rep-gb-273

Geographies analyzed under this research report include 

  • North America
  • Asia Pacific
  • Europe
  • Rest of the World

Why Buy FMI’s Report?

  • Extensive analysis on high growth niche markets across major regions
  • Detailed assessment on key segments and sub-segments
  • Recent and upcoming strategies tracked of manufacturers for the Bio Polyol and Green Polyol market
  • Reliable information on new product launches, technological advancements, and more
  • Valuable insights on the impact of regulatory framework on the global Bio Polyol and Green Polyol market

About FMI

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
LinkedIn| Twitter| Blogs